BioSpace News Archive

SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the activation of Good Samaritan Regional Medical Center in Corvallis, Oregon, as the first clinical site in its pivotal NEUTRALIZE-AKI trial.

ViaLase, Inc today announced that it will present new scientific research during the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held April 23-27, 2023 in New Orleans, Louisiana.

The Metrodora Institute today announced the opening of its state-of-the-art medical and research center, dedicated to advancing care and accelerating the path to improved diagnostics, therapeutics, and cures for patients living with neuroimmune axis disorders

Resilia Pharmaceuticals, Inc. announced today that it has re-launched Solace ® Eczema Cream on Amazon ® and restored the supply of this product that had formerly only been available by prescription.

Ajinomoto Bio-Pharma Services is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company’s high potency vial line to manufacture a commercial product.

Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that a poster highlighting the Company’s DNA-based immunotherapy IMNN-001 was presented on April 18 at the American Association for Cancer Research (AACR) Annual Meeting in Orlando.

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2023 financial results after the close of the market on Tuesday, May 9, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

OncoResponse today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.